Organ Preservation Patents

Organ preservation patents cover machine-perfusion-device innovations; perfusate and solution innovations; ex-vivo viability-assessment innovations; and reconditioning, portability, and DCD innovations — with IP held by perfusion-device companies and transplant-technology firms (in a field expanding the donor pool by keeping organs alive and assessable outside the body). MAJOR ORGAN-PRESERVATION PATENT HOLDERS: TRANSMEDICS: the Organ Care System OCS — NORMOTHERMIC (warm, ~37 °C) machine perfusion that keeps a donor heart, lung, or liver functioning ('beating'/breathing) outside the body with oxygenated blood ('organ in a box'), enabling transport, assessment, and use of marginal/DCD organs; a deep normothermic-perfusion estate. ORGANOX: the metra device for normothermic machine perfusion NMP of donor livers (perfusing the liver with warm oxygenated blood to assess and preserve it). PARAGONIX: SherpaPak and similar HYPOTHERMIC (cold) controlled oxygenated/static devices for heart, lung, liver, and kidney transport (an advance over a cooler of ice). XVIVO PERFUSION: machine perfusion for lungs (ex vivo lung perfusion EVLP) and hearts/livers, and preservation solutions. OTHERS: Bridge to Life (preservation solutions, perfusion), 34Lives, Organ Recovery Systems (LifePort hypothermic kidney perfusion), and adjacent xeno/eGenesis. Machine perfusion (normothermic vs hypothermic), perfusate, and ex vivo viability assessment are the core organ-preservation patent domains.

Perfusion-device and circuit innovations; normothermic-perfusion innovations; hypothermic and oxygenated-storage innovations; and perfusate/preservation-solution innovations represent core organ-preservation patent domains — and machine perfusion (vs static cold storage) is the technology shift that defines the field. PERFUSION-DEVICE PATENTS: the device and circuit that perfuse an organ ex vivo — pump, oxygenator, heat exchanger, organ chamber, cannulation/connections, sensors, and consumable cassette/perfusion sets; portable, self-contained transport units (TransMedics OCS) versus benchtop perfusion (OrganOx). NORMOTHERMIC PATENTS: warm (~37 °C) perfusion that keeps the organ metabolically active and FUNCTIONING (a beating heart, a metabolizing liver), enabling real-time function assessment and longer/better preservation than cold storage; oxygenation, nutrient/blood perfusate circulation, and physiologic conditioning. HYPOTHERMIC PATENTS: controlled hypothermic and hypothermic-oxygenated perfusion/storage (cold but actively perfused/oxygenated — better than ice), temperature control, and oxygen delivery. PERFUSATE / SOLUTION PATENTS: the perfusion/preservation solution composition — blood-based or acellular perfusates, oxygen carriers, nutrients, and additives that reduce ischemia-reperfusion injury; and static-preservation solutions (UW, HTK, Celsior lineage). Normothermic functional perfusion devices and the perfusate/anti-ischemia formulations are the highest-value organ-preservation IP because they enable using organs that cold storage would waste.

Ex-vivo viability-assessment innovations; organ-reconditioning and resuscitation innovations; donation-after-circulatory-death (DCD) innovations; and extended-preservation innovations represent additional organ-preservation patent domains — and assessing AND improving organs ex vivo (not just storing them) is the frontier that most expands the donor pool. VIABILITY-ASSESSMENT PATENTS: measuring organ function/viability during perfusion — for livers, lactate clearance, bile production, perfusate biochemistry; for hearts, contractility/function; for lungs, gas exchange/compliance; plus biomarkers, imaging, and decision algorithms (assessment algorithms are most defensible tied to the device/measurements, given §101) — this turns a binary accept/reject into a measured decision, enabling use of marginal organs. RECONDITIONING / RESUSCITATION PATENTS: actively improving an organ ex vivo — clearing edema, defatting a steatotic liver, treating with drugs/gene therapy/cells during perfusion, and ischemia-reperfusion-injury mitigation; ex vivo organ repair is a major emerging area. DCD PATENTS: normothermic regional perfusion NRP and machine perfusion enabling use of organs from donation after circulatory death (DCD) — a large, underused donor pool that cold storage handles poorly. EXTENDED-PRESERVATION PATENTS: prolonging viable preservation time (hours → potentially days), supercooling/partial-freezing and cryopreservation research, and logistics. Ex vivo viability assessment, organ reconditioning/repair, and DCD-enabling perfusion are the highest-value organ-preservation IP because they directly expand the supply of usable organs.

Organ preservation startup IP strategy must navigate TransMedics' normothermic-perfusion estate (and its OCS device/consumable model), OrganOx liver-perfusion patents, Paragonix/XVIVO/Organ Recovery hypothermic and EVLP patents, decades of preservation-solution and perfusion prior art, FDA device/biologic regulatory pathways and transplant-center adoption (decisive, slow gates), the device-plus-consumable business model, and a landscape where assessment and reconditioning are the frontiers; understand that basic perfusion is established, so the durable IP is in specific perfusion-device/circuit designs, normothermic functional perfusion, perfusate/anti-ischemia formulations, viability-assessment methods (tied to the device), and ex vivo reconditioning, and that the consumable/cassette model and clinical evidence matter as much as patents; identify whitespace in ex vivo reconditioning/repair, viability assessment, extended preservation, and DCD. ORGAN-PRESERVATION STARTUP IP STRATEGY: PERFUSION IS ESTABLISHED — DEVICE DESIGN, PERFUSATE, ASSESSMENT, AND RECONDITIONING ARE THE IP: patent the specific perfusion-device/circuit/cassette, normothermic functional perfusion, anti-ischemia perfusate, viability-assessment method (tied to the device), and ex vivo reconditioning — not generic perfusion; EX VIVO RECONDITIONING/REPAIR IS HIGHEST-VALUE WHITESPACE: actively improving organs ex vivo (defatting steatotic livers, clearing edema, drug/gene/cell treatment during perfusion) converts unusable organs into transplantable ones — the most impactful, patentable frontier; VIABILITY ASSESSMENT EXPANDS THE DONOR POOL: measured, algorithmic accept/use decisions (tied to perfusion measurements) let surgeons use marginal/DCD organs — patentable and clinically transformative; EXTENDED PRESERVATION AND DCD ARE GROWING WHITESPACE: prolonging viable time (toward days) and DCD-enabling perfusion unlock large underused supply; THE CONSUMABLE/CASSETTE MODEL IS THE BUSINESS — PATENT IT: device-plus-disposable (TransMedics-style) recurring revenue depends on patented consumables/perfusion sets; CLINICAL EVIDENCE AND FDA/CENTER ADOPTION ARE PARALLEL MOATS: trial outcomes (more transplants, better survival) and transplant-center uptake gate the market as much as IP; WHEN TO PATENT: NOVEL DEVICE/METHOD WITH MEASURED PERFORMANCE: file once a system shows measured results (preservation time + organ viability/function metrics + utilization-rate increase + reconditioning effect + transplant outcomes) vs. cold-storage baselines — measured preservation time, viability/function, organ-utilization increase, and outcomes are the critical organ-preservation IP metrics; KEY FTO CHECKLIST: TransMedics OCS normothermic warm-perfusion heart/lung/liver portable + consumable; OrganOx metra NMP liver lactate/bile assessment; Paragonix SherpaPak hypothermic oxygenated; XVIVO ex vivo lung perfusion EVLP + solution; Organ Recovery LifePort hypothermic kidney; perfusate blood-based/acellular oxygen-carrier anti-ischemia + UW/HTK static solution; viability assessment biomarker/algorithm (§101-tied-to-device); ex vivo reconditioning defatting/drug/gene; DCD normothermic regional perfusion; extended preservation/supercooling; FDA device/biologic pathway.